Commerzbank Aktiengesellschaft FI Raises Stock Position in Zoetis Inc. $ZTS

Commerzbank Aktiengesellschaft FI increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 51.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,854 shares of the company’s stock after buying an additional 8,145 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Zoetis were worth $1,714,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ZTS. RFG Advisory LLC grew its position in Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after acquiring an additional 80 shares during the period. Quest 10 Wealth Builders Inc. raised its position in Zoetis by 4.7% in the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after purchasing an additional 86 shares during the period. Financial Engines Advisors L.L.C. lifted its stake in shares of Zoetis by 4.4% in the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after purchasing an additional 87 shares during the last quarter. Physician Wealth Advisors Inc. lifted its stake in shares of Zoetis by 17.4% in the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after purchasing an additional 91 shares during the last quarter. Finally, Smithfield Trust Co grew its holdings in shares of Zoetis by 4.2% during the 4th quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock worth $290,000 after purchasing an additional 92 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent analyst reports. UBS Group decreased their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Morgan Stanley set a $85.00 price target on shares of Zoetis in a research report on Friday, August 7th. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Finally, Zacks Research cut shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $109.62.

Zoetis Price Performance

ZTS opened at $72.71 on Tuesday. The stock’s 50-day moving average price is $76.17 and its 200 day moving average price is $98.47. Zoetis Inc. has a 12-month low of $71.00 and a 12-month high of $160.48. The firm has a market cap of $30.05 billion, a price-to-earnings ratio of 11.98, a PEG ratio of 1.28 and a beta of 0.73. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis’s payout ratio is 34.93%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.